6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A bile acid receptor (FXR) agonist has reached the market since this programme started: obeticholic acid (Ocaliva), which was discovered by GSK in collaboration with the University of Perugia51 and subsequently developed by Intercept Pharmaceuticals.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [51]
In the citing paper
“OCA is a farnesoid X receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [156]
In the citing paper
“Obeticholic acid has approximately 100 times greater potency in activating FXR than chenodeoxycholic acid. 11”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“Obeticholic acid is a selective farnesoid X receptor (FXR) agonist that is derived from the bile acid chenodeoxycholic acid, the endogenous FXR ligand.”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“OCA, a 6α-ethyl derivate of chenodeoxycholic acid, is a steroidal FXR agonist (still maintaining its BA structure) and first-in-class therapeutic FXR ligand.94”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [94]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Self-citationNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940
Self-citationTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
The Continuing Importance of Bile Acids in Liver and Intestinal Disease
Hofmann, A. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2647 · Cited by 982
Modulation of Polyketide Synthase Activity by Accessory Proteins During Lovastatin Biosynthesis
Kennedy, J., Auclair, K., Kendrew, S. G., Park, C., Vederas, J. C., & Richard Hutchinson, C. (1999) · Science · doi:10.1126/science.284.5418.1368 · Cited by 654
Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR
Maloney, P. R., Parks, D. J., Haffner, C. D., Fivush, A. M., Chandra, G., Plunket, K. D., Creech, K. L., Moore, L. B., Wilson, J. G., Lewis, M. C., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002127 · Cited by 527
Self-citation
Research works printed but not linked: 3
- Mangelsdorf D. J., 1995, Cell, 83, 850
- Forman B. M., 1995, Cell, 81, 693
- Lu T. T., 2000, Mol. Cell, 6, 515
Cited by
Items 201–300 of 793
Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand
Li, J., Kuruba, R., Wilson, A., Gao, X., Zhang, Y., & Li, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013955 · Cited by 66
“In addition to BAs, a number of synthetic FXR agonists have been developed, among which GW4064 is one of the most potent FXR agonists [11,12].”
BackgroundBile acids and cardiovascular function in cirrhosis
Voiosu, A. M., Wiese, S. S., Voiosu, T. A., Bendtsen, F., & Møller, S. (2017) · Liver International · doi:10.1111/liv.13394 · Cited by 72
“96 It was hoped that OCA might supersede UDCA and represent an alternative for patients with primary biliary cholangitis not responding to first-line treatment.”
BackgroundPapazyan, R., Liu, X., Liu, J., Dong, B., Plummer, E. M., Lewis, R. D., Roth, J. D., & Young, M. A. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m081935 · Cited by 67
“The primary action of OCA in cholestasis is the reduction in bile acid synthesis by repression of the cytochrome P450 gene encoding cholesterol 7-hydroxylase (CYP7A1) expression and elevated expression of bile acid transporters (15) to reduce bile acid toxicity and inflammation (18).”
BackgroundYu, L., Liu, Y., Wang, S., Zhang, Q., Zhao, J., Zhang, H., Narbad, A., Tian, F., Zhai, Q., & Chen, W. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2181930 · Cited by 76
Obeticholic acid for the treatment of primary biliary cirrhosis
Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1092381 · Cited by 63
“[21] Chenodeoxycholic acid (CDCA) and its semisynthetic analog obeticholic acid (OCA) are selective ligands for FXR, with the latter illustrating exponential activation potency relative to its endogenous counterpart (Figure 1).[22] OCA also induces expression of fibroblast growth factor (FGF)-19 which could plausibly…”
BackgroundPellicciari, R., Passeri, D., Franco, F., Mostarda, S., Filipponi, P., Colliva, C., Gadaleta, R. M., Franco, P., Carotti, A., Macchiarulo, A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01126 · Cited by 72
Self-citationThe Farnesoid X Receptor: Good for BAD
Keely, S. J., & Walters, J. R. F. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.08.004 · Cited by 62
Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases
Yang, T., Khan, G. J., Wu, Z., Wang, X., Zhang, L., & Jiang, Z. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.007 · Cited by 66
Lipid‐sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome
Vacca, M., Degirolamo, C., Mariani‐Costantini, R., Palasciano, G., & Moschetta, A. (2011) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.137 · Cited by 63
Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?
Cao, H., Zhu, Y., Hu, G., Zhang, Q., & Zheng, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106586 · Cited by 68
Bass, J. Y., Caravella, J. A., Chen, L., Creech, K. L., Deaton, D. N., Madauss, K. P., Marr, H. B., McFadyen, R. B., Miller, A. B., Mills, W. Y., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.089 · Cited by 62
Self-citationNSAIDs Ibuprofen, Indometacin and Diclofenac do not interact with Farnesoid X Receptor
Schmidt, J., Klingler, F., Proschak, E., Steinhilber, D., Schubert‐Zsilavecz, M., & Merk, D. (2015) · Scientific Reports · doi:10.1038/srep14782 · Cited by 64
The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
Matteo, S. D., Nevi, L., Costantini, D., Overi, D., Carpino, G., Safarikia, S., Giulitti, F., Napoletano, C., Manzi, E., Rose, A. M. D., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210077 · Cited by 66
FXR: a target for cholestatic syndromes?
Cai, S., & Boyer, J. L. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.3.409 · Cited by 65
“Targets (2006) 10(3) Examples include GW4064, 6-ECDCA (INT-747) and fexaramine [54,110,111] (Figure 2).”
Yang, X., Sun, Y., Sun, T., & Rao, Y. (2016) · Chemical Communications · doi:10.1039/c6cc00234j · Cited by 60
Zhang, Y., Jackson, J. P., Claire, R. L. S., Freeman, K., Brouwer, K. R., & Edwards, J. E. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.329 · Cited by 64
“Obeticholic acid (OCA), a semi-synthetic analog of CDCA is approximately 100-fold more potent than CDCA (Pellicciari et al. 2002).”
BackgroundRichter, H. G., Benson, G. M., Blum, D., Chaput, E., Feng, S., Gardès, C., Grether, U., HARTMAN, P. G., Kuhn, B., Martin, R. E., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.039 · Cited by 61
Jouihan, H., Will, S., Guionaud, S., Boland, M. L., Oldham, S., Ravn, P., Celeste, A., & Trevaskis, J. L. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.001 · Cited by 59
“Promising data were recently published from the FLINT clinical trial where subjects with biopsy-confirmed NASH were treated for 72 weeks with the bile acid obeticholic acid (OCA, or 6-ethylchenodeoxycholic acid), a potent and highly selective FXR agonist synthesized from the natural bile acid chenodeoxycholic acid [9,…”
MethodCui, J. Y., Aleksunes, L. M., Tanaka, Y., Fu, Z. D., Guo, Y., Guo, G. L., Lü, H., Zhong, X., & Klaassen, C. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00370.2011 · Cited by 60
Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
Roberts, S. B., Ismail, M., Kanagalingam, G., Mason, A. L., Swain, M. G., Vincent, C., Yoshida, E. M., Tsien, C., Flemming, J. A., Janssen, H. L. A., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1518 · Cited by 58
The pathogenesis, models and therapeutic advances of primary biliary cholangitis
Li, H., Guan, Y., Han, C., Zhang, Y., Liu, Q., Wei, W., & Ma, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111754 · Cited by 64
Role of bile acids in liver diseases mediated by the gut microbiome
Shao, J., Ge, T., Chen, S., Wang, G., Yang, Q., Huang, C., Xu, L., & Chen, Z. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i22.3010 · Cited by 67
Roda, A., Pellicciari, R., Gioiello, A., Neri, F., Camborata, C., Passeri, D., Franco, F., Spinozzi, S., Colliva, C., Adorini, L., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214650 · Cited by 65
“Recently, 6a-ethyl-3a,7a-dihydroxy-5b-cholan-24-oic acid (OCA), a potent selective FXR agonist, was developed (Pellicciari et al., 2002, 2004, 2012; Gioiello et al., 2011).”
BackgroundSelf-citationRenga, B., Mencarelli, A., D'Amore, C., Cipriani, S., Baldelli, F., Zampella, A., Distrutti, E., & Fiorucci, S. (2012) · The FASEB Journal · doi:10.1096/fj.11-195701 · Cited by 59
Self-citationPark, J. W., Kim, J. H., Kim, S. E., Jung, J. H., Jang, M. K., Park, S. H., Lee, M. S., Kim, H. S., Suk, K. T., & Kim, D. J. (2022) · Biomedicines · doi:10.3390/biomedicines10061288 · Cited by 67
Wu, H., Liu, G., He, Y., Da, J., & Xie, B.-Q. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.05.022 · Cited by 61
Zaveri, N. T., & Murphy, B. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00063-8 · Cited by 64
Pathogenesis and management of pruritus in cholestatic liver disease
Imam, M. H., Gossard, A. A., Sinakos, E., & Lindor, K. D. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07109.x · Cited by 56
Clinical application of transcriptional activators of bile salt transporters
Baghdasaryan, A., Chiba, P., & Trauner, M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.12.001 · Cited by 60
Fiorucci, S., Zampella, A., Cirino, G., Bucci, M., & Distrutti, E. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00577.2016 · Cited by 55
“The expression of CSE (mRNA and protein) in HepG2 cells (a hepatocarcinoma cell line) is induced by treatment with CDCA and CA (23, 68) and 6-ethylchenodeoxycholic acid (6-ECDCA, also known as INT-747 or obeticholic acid), a semisynthetic FXR ligand (63, 68).”
BackgroundSelf-citationGarcia, M., Thirouard, L., Sèdes, L., Monrose, M., Holota, H., Caira, F., Volle, D. H., & Beaudoin, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113630 · Cited by 62
“Therefore, it has come as no surprise that the high affinity 6-ECDCA FXRα ligand was able to restore reduced bile flow and improve cholestasis in several preclinical animal models of cholestasis [102,123], as well as in patients with PBC [124].”
BackgroundDrugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
Sharma, M., Premkumar, M., Kulkarni, A. V., Kumar, P., Reddy, D. N., & Rao, N. P. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00055 · Cited by 61
“[51] Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR,”
BackgroundBile Acid Signaling in Inflammatory Bowel Disease
Bromke, M. A., & Krzystek‐Korpacka, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169096 · Cited by 55
“Soon after the discovery of BA as agonists of FXR, a semi-synthetic ligand for FXR has been reported [58].”
BackgroundMerk, D., Lamers, C., Ahmad, K. A., Gomez, R. C., Schneider, G., Steinhilber, D., & Schubert‐Zsilavecz, M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500937v · Cited by 59
Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist
Feng, S., Yang, M., Zhang, Z., Wang, Z., Hong, D., Richter, H. G., Benson, G. M., Bleicher, K., Grether, U., Martin, R. E., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.008 · Cited by 55
Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases
Stanimirov, B., Stankov, K., & Mikov, M. (2015) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(14)60307-6 · Cited by 59
Reciprocal interactions between bile acids and gut microbiota in human liver diseases
Ikegami, T., & Honda, A. (2018) · Hepatology Research · doi:10.1111/hepr.13001 · Cited by 55
Cipriani, S., Renga, B., D’Amore, C., Simonetti, M., Tursi, A. A. D., Carino, A., Monti, M. C., Sepe, V., Zampella, A., & Fiorucci, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129866 · Cited by 56
Self-citationFarnesoid X receptor represses hepatic lipase gene expression
Sirvent, A., Verhoeven, A. J. M., Jansen, H., Kosykh, V., Darteil, R. J., Hum, D. W., Fruchart, J.-C., & Staels, B. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400221-jlr200 · Cited by 54
“In addition to BAs, synthetic FXR agonists have also been identified (11, 12).”
BackgroundLeva, F. S. D., Festa, C., D’Amore, C., Marino, S. D., Renga, B., D’Auria, M. V., Novellino, E., Limongelli, V., Zampella, A., & Fiorucci, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400419e · Cited by 56
Self-citationSchramm, C., Wedemeyer, H. H., Mason, A. L., Hirschfield, G. M., Levy, C., Kowdley, K. V., Milkiewicz, P., Janczewska, E., Malova, E. S., Sanni, J., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100544 · Cited by 60
“The farnesoid X receptor (FXR) has long been a target of interest for intrahepatic cholestasis.(10,11) The bile acid FXR agonist obeticholic acid (OCA) has been clinically validated in multiple phase II and III studies and has been approved in combination with UDCA for patients with PBC having an inadequate response t…”
BackgroundErichsen, T. J., Aehlen, A., Ehmer, U., Kalthoff, S., Manns, M. P., & Strassburg, C. P. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.010 · Cited by 54
“The primary BA CDCA is a potent activator and a ligand of FXR [12].”
BackgroundLundquist, J. T. I., Harnish, D. C., Kim, C. Y., Mehlmann, J. F., Unwalla, R. J., Phipps, K. M., Crawley, M. L., Commons, T., Green, D. M., Xu, W., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901650u · Cited by 54
Targeting FXR in cholestasis: hype or hope
Fiorucci, S., Distrutti, E., Ricci, P., Giuliano, V., Donini, A., & Baldelli, F. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.956087 · Cited by 61
“In a cell-free ligand sensing assay, which measures the ligand-dependent recruitment of an SRC1 peptide to FXR by fluorescence resonance energy transfer, the relative EC50 for FXR was originally reported to be 85 nM [31].”
Self-citationRecent advances in understanding and managing cholestasis
Wagner, M., & Trauner, M. (2016) · F1000Research · doi:10.12688/f1000research.8012.1 · Cited by 55
de Oliveira, M. C., Gilglioni, E. H., de Boer, B. A., Runge, J. H., de Waart, D. R., Salgueiro, C. L., Ishii‐Iwamoto, E. L., Elferink, R. P. J. O., & Gaemers, I. C. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.07.012 · Cited by 56
Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis
Venetsanaki, V., Karabouta, Z., & Polyzos, S. A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172661 · Cited by 52
Chen, P., Li, J., Fan, X., Zeng, H., Deng, R., Li, D., Huang, M., & Bi, H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.029 · Cited by 55
“Fiorucci group demonstrated that a selective FXR agonist 6-ECDCA provided protective effect in murine models of LCA or estrogen-induced cholestasis (Fiorucci et al., 2005; Pellicciari et al., 2002).”
BackgroundPatented TGR5 modulators: a review (2006 – present)
Gioiello, A., Rosatelli, E., Nuti, R., Macchiarulo, A., & Pellicciari, R. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.733000 · Cited by 58
“When the 23(S)-methyl group was next introduced in 6-ECDCA (Obeticholic acid, INT-747, 5) [37], a potent and selective FXR agonist in Phase III clinical studies for primary biliary cirrhosis (PBC) and non-alcoholic steatohepatitis (NASH), a reversal of the activity profile was observed.”
BackgroundSelf-citationFarnesoid X Receptor an Emerging Target to Combat Obesity
Filho, C. D. D. M., Downes, M., & Evans, R. M. (2017) · Digestive Diseases · doi:10.1159/000450909 · Cited by 54
Recent advances in the management of pruritus in chronic liver diseases
Tajiri, K., & Shimizu, Y. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i19.3418 · Cited by 58
Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease
Yu, Q., Jiang, Z., & Zhang, L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.005 · Cited by 56
“OCA activates FXR (de Oliveira et al., 2016; Pellicciari et al., 2002).”
MASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
Pellicciari, R., Gioiello, A., Costantino, G., Sadeghpour, B. M., Rizzo, G., Meyer, U., Parks, D. J., Entrena-Guadix, A., & Fiorucci, S. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060294k · Cited by 53
Self-citationFarnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
Li, C., Yang, J., Wang, Y., Qi, Y., Yang, W., & Li, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01247 · Cited by 55
“The first FXR agonist that was investigated in clinical practice was obeticholic acid (OCA), which has an ethyl group substituted at the 6 position of CDCA, which is the most potent natural ligand activator of FXR (Pellicciari et al., 2002).”
BackgroundEnterohepatic circulation of bile acids and their emerging roles on glucolipid metabolism
Chen, M., Liu, C., Wan, Y., Yang, L., Jiang, S., Qian, D., & Duan, J. (2020) · Steroids · doi:10.1016/j.steroids.2020.108757 · Cited by 55
Nevens, F., Trauner, M., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 55
Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation
Schuster, D., Markt, P., Grienke, U., Mihaly‐Bison, J., Binder, M., Noha, S. M., Rollinger, J. M., Stuppner, H., Bochkov, V. N., & Wolber, G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.056 · Cited by 52
Obeticholic acid for the treatment of primary biliary cholangitis
Ali, A. H., & Lindor, K. D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1218471 · Cited by 47
Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
Edwards, J., LaCerte, C., Peyret, T., Gosselin, N., Marier, J., Hofmann, A., & Shapiro, D. (2016) · Clinical and Translational Science · doi:10.1111/cts.12421 · Cited by 50
Old and new treatments for primary biliary cholangitis
Chascsa, D. M. H., Carey, E. J., & Lindor, K. D. (2017) · Liver International · doi:10.1111/liv.13294 · Cited by 56
Sepe, V., Marchianò, S., Finamore, C., Baronissi, G., Leva, F. S. D., Carino, A., Biagioli, M., Fiorucci, C., Cassiano, C., Monti, M. C., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00423 · Cited by 50
Self-citationMedicinal Chemistry Of Farnesoid X Receptor Ligands: From Agonists And Antagonists To Modulators
Merk, D., Steinhilber, D., & Schubert‐Zsilavecz, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.47 · Cited by 52
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 53
“FXR regulates BA synthesis by several mechanisms, directly or through the orphan NR small heterodimer partner [33,34].”
BackgroundKainuma, M., Takada, I., Makishima, M., & Sano, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071898 · Cited by 52
“Chenodeoxycholic acid (CDCA) is a potent natural FXR agonist [3] and GW4064 and obeticholic acid (OCA) are synthetic agonists [16,17], while guggulsterone (GS) is an FXR antagonist that has been identified as the cholesterol-lowering agent in the extract of the guggul tree [18].”
BackgroundHouten, S., & Auwerx, J. (2004) · Annals of Medicine · doi:10.1080/07853890410018790 · Cited by 47
Farnesoid X receptor agonists for primary biliary cirrhosis
Lindor, K. D. (2011) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834452c8 · Cited by 49
Hsu, C.-W., Zhao, J., Huang, R., Hsieh, J., Hamm, J. T., Chang, X., Houck, K. A., & Xia, M. (2014) · Scientific Reports · doi:10.1038/srep06437 · Cited by 55
Marinozzi, M., Carotti, A., Sansone, E., Macchiarulo, A., Rosatelli, E., Sardella, R., Natalini, B., Rizzo, G., Adorini, L., Passeri, D., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.021 · Cited by 49
Self-citationOlğaç, A., Orhan, İ. E., & Banoğlu, E. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0124 · Cited by 56
Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
Zhou, M., Wang, D., Li, X., Cao, Y., Yi, C., Ocansey, D. K. W., Zhou, Y., & Mao, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016836 · Cited by 56
“However, under the action of 6alpha-ethylchenodeoxycholic acid (6-ECDCA), also known as INT-747 and OCA (Pellicciari et al., 2002; Fiorucci et al., 2022), the FXR/SHP signaling axis is effectively activated and the development of inflammation is inhibited (Mencarelli et al.”
BackgroundCarino, A., Biagioli, M., Marchianò, S., Fiorucci, C., Bordoni, M., Roselli, R., Giorgio, C. D., Baldoni, M., Ricci, P., Monti, M. C., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158733 · Cited by 48
Self-citationJian, J., Nie, M., Xiang, B., Qian, H., Yin, C., Zhang, X., Zhang, M. H., Zhu, X., & Xie, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841132 · Cited by 53
“A semisynthetic derivative of CDCA named obeticholic acid (OCA) is an agonist of FXR (Pellicciari et al., 2002).”
BackgroundNew Therapeutic Strategies for Primary Sclerosing Cholangitis
Williamson, K., & Chapman, R. (2016) · Seminars in Liver Disease · doi:10.1055/s-0035-1571274 · Cited by 46
Sepe, V., Ummarino, R., D’Auria, M. V., Chini, M. G., Bifulco, G., Renga, B., D’Amore, C., Debitus, C., Fiorucci, S., & Zampella, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201004p · Cited by 46
Self-citationHaczeyni, F., Poekes, L., Wang, H., Mridha, A. R., Barn, V., Geoffrey Haigh, W., Ioannou, G. N., Yeh, M. M., Leclercq, I. A., Teoh, N. C., et al. (2017) · Obesity · doi:10.1002/oby.21701 · Cited by 46
“receptor (FXR) (15,17), a nuclear receptor which, by regulating the expression of other transcription factors, reduces lipogenesis, suppresses de novo cholesterol biosynthesis, and increases b-oxidation of long chain FAs (18,19).”
BackgroundLiu, X., Guo, G. L., Kong, B., Hilburn, D. B., Hubchak, S. C., Park, S., LeCuyer, B., Hsieh, A., Wang, L., Fang, D., et al. (2018) · Hepatology · doi:10.1002/hep.29815 · Cited by 46
“The high-affinity FXR agonist, 6-ECDCA, has hepatoprotective effects including reduction in inflammation and fibrosis, improving biliary transport, regulating hepatic glucose and lipid metabolism, and regulating antiapoptotic pathways.((30-33)) 6-ECDCA has been approved for the treatment of primary biliary cholangitis…”
BackgroundWagner, M., & Trauner, M. (2005) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32071-x · Cited by 53
Linking liver metabolic and vascular disease via bile acid signaling
Fiorucci, S., & Distrutti, E. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.10.005 · Cited by 49
Self-citationNovel bile acid therapeutics for the treatment of chronic liver diseases
Hegade, V. S., Speight, R. A., Etherington, R. E., & Jones, D. E. J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16630712 · Cited by 44
“OCA is a steroidal semisynthetic BA in which CDCA has been modified by the addition of an alkyl group to form a more potent FXR agonist [Pellicciari et al. 2002].”
BackgroundRole of farnesoid X receptor in cholestasis
Yuan, Z. Q., & Li, K. W. (2016) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12378 · Cited by 46
Obeticholic Acid Ameliorates Valproic Acid–Induced Hepatic Steatosis and Oxidative Stress
Gai, Z., Krajnc, E., Samodelov, S. L., Visentin, M., & Kullak-Ublick, G. A. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.118646 · Cited by 52
“…whereas constitutive activation of FXR reduces steatosis, hepatic inflammation, and fibrosis in animals with nonalcoholic fatty liver disease (Pellicciari et al., 2002; Fiorucci et al., 2005; Zhang et al., 2009; Lívero et al., 2014; Gai et al., 2018) and prevents carcinogenesis in…”
BackgroundIto, K., Okumura, A., Takeuchi, J. S., Watashi, K., Inoue, R., Yamauchi, T., Sakamoto, K., Yamashita, Y., Iguchi, Y., Une, M., et al. (2021) · Hepatology · doi:10.1002/hep.31712 · Cited by 47
Cai, S.-Y., Xiong, L., Wray, C. G., Ballatori, N., & Boyer, J. L. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00781.2006 · Cited by 44
The farnesoid X receptor: a novel drug target?
Claudel, T., Sturm, E., Kuipers, F., & Staels, B. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1135 · Cited by 47
“The LCA-induced cholestasis model is another model of intrahepatic cholestasis in which the CDCA derivate 6-ECDCA, a high affinity FXR ligand, was tested [17].”
BackgroundBile acid metabolism and FXR-mediated effects in human cholestatic liver disorders
Molinaro, A., & Marschall, H. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210658 · Cited by 47
Bowlus, C. (2016) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s91709 · Cited by 42
“…the primary human BA, and is the natural ligand for FXR. OCA is approximately 100 times more potent as an FXR ligand than chenodeoxycholic acid 24 and demonstrates high selectivity with minimal activity to the another described BA receptor, G protein-coupled bile acid receptor 1 (GPBAR1 or…”
New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
Jhaveri, M., & Kowdley, K. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s113052 · Cited by 43
“Obeticholic acid OCA (6α-ethyl-chenodeoxycholic acid) is a selective farnesoid-X-receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid that has been modified chemically to make it 100 times more potent than chenodeoxycholic acid.(42,43) The FXR nuclear receptor is expressed in the liver…”
Obeticholic acid for the treatment of nonalcoholic steatohepatitis
Shah, R. A., & Kowdley, K. V. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1748498 · Cited by 47
“of a 6α-ethyl substituent, and is a potent and selective farnesoid X receptor (FXR) agonist [45].”
BackgroundGioiello, A., Macchiarulo, A., Carotti, A., Filipponi, P., Costantino, G., Rizzo, G., Adorini, L., & Pellicciari, R. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.03.004 · Cited by 46
Self-citationKim, D.-H., Park, J. S., Choi, H., Kim, C. S., Bae, E. H., Kwon, S., & Kim, S. W. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00932-2 · Cited by 46
Gardès, C., Chaput, E., Staempfli, A., Blum, D., Richter, H., & Benson, G. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m033423 · Cited by 42
Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist
Kainuma, M., Makishima, M., Hashimoto, Y., & Miyachi, H. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.046 · Cited by 41
Bile Acids, Nuclear Receptors and Cytochrome P450
Juřica, J., Dovrtělová, G., Nosková, K., & Zendulka, O. (2016) · Physiological Research · doi:10.33549/physiolres.933512 · Cited by 44
Carino, A., Biagioli, M., Marchianò, S., Scarpelli, P., Zampella, A., Limongelli, V., & Fiorucci, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.033 · Cited by 44
Self-citationThe Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease
Ni, Y., Lu, M., Xu, Y., Wang, Q., Gu, X., Li, Y., Zhuang, T., Xia, C., Zhang, T., Gou, X., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.908011 · Cited by 48
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators
Pellicciari, R., Gioiello, A., Sabbatini, P., Venturoni, F., Nuti, R., Colliva, C., Rizzo, G., Adorini, L., Pruzanski, M., Roda, A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200256d · Cited by 42
Self-citationVignozzi, L., Morelli, A., Cellai, I., Filippi, S., Comeglio, P., Sarchielli, E., Maneschi, E., Vannelli, G. B., Adorini, L., & Maggi, M. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.07.004 · Cited by 42
Self-citationBiology of Cholangiocytes: From Bench to Bedside
Yoo, K.-S., Lım, W., & Choi, H. S. (2016) · Gut and Liver · doi:10.5009/gnl16033 · Cited by 57
Semisynthetic bile acids: a new therapeutic option for metabolic syndrome
Lazarević, S., Đanić, M., Goločorbin-Kon, S., Al‐Salami, H., & Mikov, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104333 · Cited by 42
Metadata
- Authors
- Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M.
- Affiliations
- University of Perugia (IT)
- Corresponding author
- Pellicciari, Roberto
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-07-20
- Volume
- 45
- Issue
- 17
- Pages
- 3569-3572
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2049515100
- Cited by
- 743
- References
- 15
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 32 · 2023: 33 · 2022: 46 · 2021: 47 · 2020: 54 · 2019: 46 · 2018: 52 · 2017: 60 · 2016: 49 · 2015: 38 · 2014: 35 · 2013: 27 · 2012: 31
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- farnesoid X receptor agonist, cholestasis, bile acid synthesis inhibition, receptor selectivity
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anticholesteremic Agents, Cell Line, Chenodeoxycholic Acid, Cholestasis, DNA-Binding Proteins, Humans, Ligands, Liver, Structure-Activity Relationship, Transcription Factors, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.